Cart

YOUR CART IS EMPTY

Add research compounds to begin your order.

Exact TB-500 identity and direct-fragment evidenceSee approved evidence mapCompleted

Drug Testing and Analysis

TB5-STUDY-P002

Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing an

Study design

Record details

Design: Exact TB-500 identity and direct-fragment evidence

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P002Exact TB-500 identity and direct-fragment evidence

Drug Testing and Analysis

Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(9):733–738. DOI: 10.1002/dta.1402. PMID: 22962027. https://pubmed.ncbi.nlm.nih.gov/22962027/(2012). DOI: 10.1002/dta.1402